What is the reason behind the failure of 1.2 million injections of anti cancer drugs to negotiate me

Because ** didn't talk about it.

The normal ** of this drug is 1.2 million yuan per injection. What everyone expects is 800,000 or 900,000. In this way, a little reimbursement is completely acceptable for middle-class families, but the end result is that anti-cancer drugs cannot be covered by medical insurance.

The main reason is **, and the ** given by the negotiation team is unacceptable to the pharmaceutical party, so the negotiation failed.

I have long expected the failure of this negotiation, because I think the expectation of the drug before the negotiation is a bit high, and the normal selling price is always 1.2 million yuan, but the negotiation team directly cut the ** to 800,000 or 900,000 yuan, which will definitely not succeed, even if it is to buy vegetables in the vegetable market.

Actually, I don't think you need to be too disappointed and sad. Don't worry about this drug not being included in the medical insurance list in the end. We can think differently.

Even if this anti-cancer drug is included in the medical insurance, what can it do? And how many people can afford it? After all, it costs so much money that it is not a medicine that ordinary working families can afford at all.

For rare diseases and drugs, unless there are tens of billions of spare money in medical insurance every year, we can't afford to use them. These newly marketed anti-cancer drugs are very expensive. If it is included in the medical insurance catalogue as soon as it is listed, it will bring great pressure to the total cost of medical insurance.

In fact, more and more anti-cancer drugs are now included in medical insurance, which was unthinkable in the past. In addition, even for new anti-cancer drugs not covered by medical insurance, with the reduction of tariffs and the intensity of drug price negotiations, the ** of many of the latest anti-cancer targeted drugs and immune drugs has been maintained at a very low level, which can be said to be a great progress, which is still worth affirming.

I think it was because the negotiation failed, and it was originally expected to be negotiated for 80-900,000 yuan, but the other party was unwilling to reduce the price, so the negotiation failed.

Because of the reason that it is too high, it is too high, and some of the pharmaceutical aspects have a way to accept it, so it leads to failure.

Mainly for economic reasons. At this stage, the medical insurance system mainly meets the basic medical security needs of the public, helps to finance and reduce the risk of low- and medium-risk diseases.

It's because there is no negotiation, and this** the other party can't accept it.

First, the research of this drug is complex, time-consuming, costly, and pay-back, so the price is high.

Second, as a result of the monopoly of drug research, developed countries have mastered the core technology and monopolized it.

Third, there is still a long way to go before patent fees and patents become popular.

This drug is mainly tens of thousands of active immune cells, packed in an infusion bag, and then injected into the patient at one time, two months later, the active immune cells will kill the cancer cells in the patient's body, to achieve zero, so as to achieve the effect of **cancer. This method is different from the traditional chemotherapy method, and it is called the cell anti-cancer method.

In the process of research and invention of high-tech products, the state has to invest a lot of manpower and financial resources, consume a lot of time and energy of scientists, and burn brain cells. The selection and configuration of instruments and equipment, materials and materials all require excellence and calculation, which is not something that we ordinary people can understand.

If this drug really enters the medical insurance, the state does not know how much it will cost. People spend a lot of money on R&D drugs, and they are not engaged in charity, and the annual salary of R&D personnel is hundreds of thousands or even millions, not to mention a team as large as a medical institution.

The purpose of medical insurance has always been to ensure that as many people as possible enjoy low-cost medical care, for rare diseases and sky-high drugs, unless the annual medical insurance ** can not spend tens of billions of spare money.

Medical insurance, in fact, is the abbreviation of basic medical insurance, the so-called basic medical insurance, of course, not all expenses can be reimbursed, medical insurance costs are limited, it is still necessary to set up a medical insurance catalog, which is also to protect the interests of the majority.

Like these newly listed anti-cancer drugs, it is very expensive, if it is included in the medical insurance catalog as soon as it is listed, it will bring a lot of pressure to the total cost of medical insurance, in the case of limited disposable expenses of the total medical insurance, similar to 1.2 million high-cost anti-cancer drugs have not entered the medical insurance, I basically still have an attitude of recognition.

Of course, everyone wants to be covered by medical insurance, which goes without saying, isn't the key still money? Money from **? So it's a real problem.

In fact, now there are more and more anti-cancer drugs, including targeted drugs, have been included in the medical insurance, such as ritosis, Herceptin, Iresa and other anti-cancer targeted drugs have been significantly reduced in price and included in the medical insurance, which was unimaginable before, that is, some cancer patients can pay a small amount of money to use these effective anti-cancer targeted drugs.

In addition, even if there are no new anti-cancer drugs that have entered the medical insurance, with the decline of tariffs and the strength of drug price negotiations, many of the latest anti-cancer targeted drugs and immune drugs have been very low, which can be said to be a big progress and is very worthy of recognition.

The purpose of medical insurance has always been to ensure that as many people as possible can enjoy low-cost medical care, but the research and development cost of this drug is really high, which will bring a lot of pressure to the total cost of medical insurance.

Because it's expensive. From the patient's point of view, only a very small number of patients have the ability to pay, and most patients can only shy away from this **. From the perspective of medical insurance**, there may not be many patients, but it will still affect the medical protection of other people.

Because the cost of this drug is too large, and the number of cancer patients in China is increasing, if it is to be included in medical insurance, the state does not have so much money to invest in this aspect.

10 billion injections of all kinds of cancer can be cured, but a few people have 10 billion ......

1.2 million injections of anti-cancer drugs are not reimbursed by medical insurance. 1.2 million injections of anti-cancer drugs have not been included in medical insurance, but many places across the country have been included in Huimin Insurance. Medical insurance generally refers to basic medical insurance, which is a social insurance system established to compensate workers for economic losses caused by the risk of disease.

Through the employer and individual payment, the establishment of medical insurance**, after the insured person is sick and incurs medical expenses, the medical insurance institution will give him a certain amount of economic compensation.

Legal basisArticle 28 of the Social Insurance Law of the People's Republic of China.

Medical expenses that meet the basic medical insurance drug list, diagnosis and treatment items, medical service facility standards, and emergency and rescue medical expenses shall be paid from the basic medical insurance in accordance with national regulations.

What is the process of medical insurance payment?

1. Application acceptance. The collection department of the medical insurance institution accepts the "Declaration Form for Change of Medical Insurance Payment Base" filled in by the insured unit, and requires the corresponding information;

2. Payment verification.

1) The collection department of the medical insurance institution shall review the payment declaration and verification ** and relevant information filled in by the insured unit. After the examination is passed, the procedures for the verification or increase or decrease of the insured personnel shall be handled;

2) According to the payment declaration and verification situation, the collection department of the medical insurance institution shall record the insurance time, current payment salary and other information for the newly insured persons in a timely manner. The collection department of the medical insurance institution shall verify the current payment base according to the declaration of the insured unit;

3. Fee collection. Medical insurance institutions can charge fees through the opening bank of "income account deposit", or they can collect fees by check, cash, wire transfer, cashier's check, etc., and issue special collection vouchers;

4. Pay the arrears. According to the arrears of medical insurance, the collection department of the medical insurance institution shall establish the arrears data and information, fill in the "Notice of Supplementary Payment of Social Insurance Premiums", and notify the insured units to make up the arrears.

The significance of health insurance negotiation is that it can further reduce the number of drugs, thereby reducing the burden on patients. Many diseases are not available for the time being, and even if they can, they may need to spend a lot of money, and these expenses are a serious burden for ordinary families, so some people may save money and give up**.

China is indeed able to build a sound social security system, and it can also bring more residents into the social security system. When more and more residents are able to enjoy the benefits of national development and successfully reduce the pressure, our country will be able to truly achieve the goal of working for the welfare of the people. What is the significance of the 1.2 million injections of sky-high anti-cancer drugs into the medical insurance negotiations?

I think there are three implications:

First, this is conducive to improving the efficiency of the first class. Second, this is conducive to promoting the development of medicine. Third, it is conducive to reducing the concerns of patients.

These are the three meanings of my analysis.

In order to make medicines affordable for people, so that many drugs can be reimbursed, and to prolong people's lives, medical insurance negotiations are to ease the pressure on people's lives.

After testing, this anti-cancer drug is indeed very effective, but it cannot be ignored that it is also very expensive. The average price of this anti-cancer drug on the market has reached 1.2 million yuan per injection, no matter what kind of family, 1.2 million is not a small number, not to mention that for families with poor economic ability, 1.2 million is an absolute sky-high price. Therefore, if this drug can be included in medical insurance, then it will bring good news to many families of cancer patients.

Even if it can only be used for lymphoma, it can save a lot of lives.

This anti-cancer drug is mainly used for lymphoma, and it is not possible to do any cancer for the time being. Therefore, citizens should still keep a normal mind and not be misjudged by the deliberate propaganda of some ** and misjudge the miracle of this anti-cancer drug.

Diffuse large B-cell lymphoma that can hide in the body's immune cells.

1.2 million injections of "anti-cancer miracle drug" for medical insurance negotiations, to be honest, no one can say how much can be cut, but I think that it is basically impossible to "within 100,000 yuan" and "within 10,000 yuan" expected by netizens, after all, the cost is there. We still have to wait for the official announcement of how much it will cost at our own expense in the future, and how much this anti-cancer miracle drug will sell depends on the negotiation results of the Health Insurance Bureau.

At present, the price of the drug is too high to exceed the affordability of ordinary families, and the Health Insurance Bureau is actively negotiating with pharmaceutical companies this time, hoping that the drug can be reduced and widely sold in the Chinese market to save more and more cancer patients. It is believed that through the unremitting efforts of the Medical Insurance Bureau, the ** of this drug can be lowered.

Among the drugs participating in the negotiation this time, the most concerned is the popular "anti-cancer miracle drug", which is rumored on the Internet that cancer cells can be cleared with one injection. However, only 1 injection costs 1.2 million yuan, which is really sky-high, and many families cannot afford it, but medical insurance negotiations may be able to reduce some of the burden.

Medical insurance negotiation refers to the negotiation between experts from the National Health Insurance Administration and pharmaceutical companies to negotiate drugs, so as to reduce drugs, reduce the economic pressure of patients, and solve the problems of difficult and expensive drugs for countless families. You can find that expensive drugs such as the new anti-tumor drug PD-1 and sintilimab have become "people-friendly" because of medical insurance.

At present, two CAR-T products have been approved in China, including: Fosun Kite's Axileucel Injection (trade name: Yikaida) and JW Therapeutics' Relma-Orencel Injection (trade name:

However, due to the medical insurance negotiation rules, the participating products need to be approved for marketing before June 30, and the latter is a product approved in September, so it will not participate in this negotiation. So this CAR-T is the "standout" in this negotiation arena.

However, I have to say one thing about the "anti-cancer miracle drug", which actually needs to be "privately customized". Patients need a doctor's professional evaluation to determine whether the ** is suitable for use. Because CAR-T needs to extract T cells from the patient's body, it only has a specific effect on the currently fixed patients, and cannot be mass-produced and then applied to others; Among them, it is also necessary to take into account the cumbersome formulation process such as the experimentation and training of professionals, so there is a reason why it is more expensive.

However, with the emergence of domestic innovative drugs, homogeneous competition is also more serious, many companies will choose to significantly reduce prices in order to gain a larger market share in order to obtain the qualification to enter the medical insurance and the huge advantage compared with competing products, so there will be a wonderful battle on the negotiation field, hoping that with time, more good drugs will be included in the medical insurance, reduce the burden of patients, and benefit the people!

In the future, it is estimated that it will cost about 300,000 yuan at out-of-pocket expense, and if it is included in the medical insurance, the medical insurance will bear most of the cost, and the individual will only bear about 30%.

In the future, it may cost tens of thousands of yuan or hundreds of thousands of yuan at its own expense, and now this ** is indeed very high, and it should be reduced a lot after the negotiation, and it will not continue to be so high**.

It is estimated that it will cost more than 200,000 yuan, because it is very expensive.

We have no way to determine how much money will be spent at our own expense in the future, after all, it is the future, but I think the future will definitely be able to do without so much money, after all, technology is constantly advancing.

First, I think a needle of ** can be cut to less than 1 million yuan.

Second, what is the function of this medicine?

Third, after being included in medical insurance, it can help others pay a little less.